drugset / Trial / NCT04699643
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1/2
Unknown
80 enrolled
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Medidata Solutions · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of EVER4010001 in combination with Pembrolizumab in Patients with Advanced Solid Tumors. And in phase II to assess the anti-tumor efficacy of EVER4010001 in combination with Pembrolizumab in treating selected indications using appropriate biomarkers.
Timeline
- Start
- 2020-07-30
- Primary completion
- 2023-06
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVER4010001 | Unknown | 40 mg | — |
| Subject | EVER4010001 | Unknown | 60 mg | — |
| Subject | EVER4010001 | Unknown | 80 mg | — |
| Subject | EVER4010001 | Unknown | 100 mg | — |
| Subject | EVER4010001 | Unknown | 120 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |